{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:56:48Z","timestamp":1793332608198,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"agricultural and social development project of Hangzhou","award":["no. 20211231Y025"],"award-info":[{"award-number":["no. 20211231Y025"]}]},{"name":"agricultural and social development project of Hangzhou","award":["no. 202204B11"],"award-info":[{"award-number":["no. 202204B11"]}]},{"DOI":"10.13039\/501100012175","name":"Zhejiang Traditional Chinese Medicine Administration","doi-asserted-by":"publisher","award":["no. 851100G02309\uff1bno. 851100G02312"],"award-info":[{"award-number":["no. 851100G02309\uff1bno. 851100G02312"]}],"id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Neurosurg Jl"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Gliomas represent the most prevalent primary neoplasm in the adult central nervous system. Despite advancements in therapeutic modalities, such as surgical intervention, radiotherapy, chemotherapy, and tumor treatment, the 5-year survival rate of glioma patients remains low. Therefore, there is an urgent need to develop additional treatment methods. Recent studies have suggested that FAM111B is involved in DNA repair, cell cycle regulation, and apoptosis. FAM111B mutations and overexpression are related to cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We found that FAM111B was significantly overexpressed in glioma tissues compared to the adjacent tissues by analyzing data from the TCGA_GBM&amp;LGG and CGGA databases. Moreover, overexpression of FAM111B was associated with shorter overall survival, and disease-specific survival and tended to increase with disease stage progression. Cellular experiments confirmed these results. These results suggest that overexpression of FAM111B promotes the proliferation, migration, and invasion of glioma cells, whereas the knockdown of FAM111B inhibits these activities. We also found that FAM111B regulated glioma cell proliferation, migration, and invasion via the PI3K\/AKT pathway.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>FAM111B is capable of enhancing the proliferation, invasion, and migration capabilities of glioma cells and promotes the malignant progression of glioma via the PI3K\/Akt signaling pathway.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This is the first study to demonstrate that FAM111B plays a crucial role in the proliferation, migration, and invasion of glioma cells. The malignant phenotype of FAM111B has also been shown to be closely associated with the PI3K\/AKT pathway. FAM111B may be a predictive biomarker and a potential therapeutic target for gliomas.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41016-025-00395-6","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:25:02Z","timestamp":1747628702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of FAM111B in the malignant progression and molecular regulation of human glioma through the PI3K\/Akt pathway"],"prefix":"10.1186","volume":"11","author":[{"given":"Heng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junrou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"10412","key":"395_CR1","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","volume":"402","author":"MJ van den Bent","year":"2023","unstructured":"van den Bent MJ, et al. Primary brain tumours in adults. Lancet. 2023;402(10412):1564-1579.2.","journal-title":"Lancet."},{"issue":"3","key":"395_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2159-8290.CD-20-1474","volume":"11","author":"JG Nicholson","year":"2021","unstructured":"Nicholson JG, et al. Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov. 2021;11(3):575\u201390.","journal-title":"Cancer Discov."},{"issue":"1","key":"395_CR3","first-page":"10373","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M, et al. Glioma Nat Rev Dis Primers. 2024;10(1):10373.","journal-title":"Glioma Nat Rev Dis Primers"},{"issue":"10","key":"395_CR4","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202050662","volume":"21","author":"S Hoffmann","year":"2020","unstructured":"Hoffmann S, et al. FAM111 protease activity undermines cellular fitness and is amplified by gain-of-function mutations in human disease. EMBO Rep. 2020;21(10): e50662.","journal-title":"EMBO Rep"},{"issue":"1","key":"395_CR5","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41467-020-15170-7","volume":"11","author":"Y Kojima","year":"2020","unstructured":"Kojima Y, et al. FAM111A protects replication forks from protein obstacles via its trypsin-like domain. Nat Commun. 2020;11(1):1318.","journal-title":"Nat Commun"},{"issue":"6","key":"395_CR6","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ajhg.2013.10.013","volume":"93","author":"S Mercier","year":"2013","unstructured":"Mercier S, et al. Mutations in FAM111B cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. Am J Hum Genet. 2013;93(6):1100\u20137.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"395_CR7","doi-asserted-by":"publisher","first-page":"111996","DOI":"10.1016\/j.celrep.2023.111996","volume":"42","author":"V Alvarez","year":"2023","unstructured":"Alvarez V, et al. Proteomic profiling reveals distinct phases to the restoration of chromatin following DNA replication. Cell Rep. 2023;42(1):111996.","journal-title":"Cell Rep"},{"issue":"1","key":"395_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s42003-020-01539-3","volume":"4","author":"A Ruggiano","year":"2021","unstructured":"Ruggiano A, Ramadan K. DNA-protein crosslink proteases in genome stability. Commun Biol. 2021;4(1):11.","journal-title":"Commun Biol"},{"issue":"12\u201313","key":"395_CR9","doi-asserted-by":"publisher","first-page":"2200220","DOI":"10.1002\/pmic.202200220","volume":"24","author":"V Munro","year":"2024","unstructured":"Munro V, et al. Cellular control of protein levels: a systems biology perspective. Proteomics. 2024;24(12\u201313):2200220.","journal-title":"Proteomics"},{"key":"395_CR10","doi-asserted-by":"publisher","first-page":"932167","DOI":"10.3389\/fonc.2022.932167","volume":"12","author":"A Arowolo","year":"2022","unstructured":"Arowolo A, et al. Proposed cellular function of the human FAM111B protein and dysregulation in fibrosis and cancer. Front Oncol. 2022;12:932167.","journal-title":"Front Oncol"},{"key":"395_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fcell.2015.00016","volume":"3","author":"E Aleem","year":"2015","unstructured":"Aleem E, Arceci RJ. Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol. 2015;3:16.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"395_CR12","doi-asserted-by":"publisher","first-page":"e20200332","DOI":"10.1590\/1678-4685-gmb-2020-0332","volume":"44","author":"G Roversi","year":"2021","unstructured":"Roversi G, et al. Spontaneous chromosomal instability in peripheral blood lymphocytes from two molecularly confirmed Italian patients with Hereditary Fibrosis Poikiloderma: insights into cancer predisposition. Genet Mol Biol. 2021;44(3):e20200332.","journal-title":"Genet Mol Biol"},{"key":"395_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13023-015-0352-4","volume":"10","author":"S Mercier","year":"2015","unstructured":"Mercier S, et al. Expanding the clinical spectrum of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis due to FAM111B mutations. Orphanet J Rare Dis. 2015;10:135.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"395_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1172\/JCI31487","volume":"117","author":"TA Wynn","year":"2007","unstructured":"Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117(3):524\u20139.","journal-title":"J Clin Invest"},{"key":"395_CR15","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.2147\/OTT.S190934","volume":"12","author":"H Sun","year":"2019","unstructured":"Sun H, et al. FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma. Onco Targets Ther. 2019;12:2829\u201342.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"395_CR16","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1111\/cas.14483","volume":"111","author":"K Kawasaki","year":"2020","unstructured":"Kawasaki K, et al. FAM111B enhances proliferation of KRAS-driven lung adenocarcinoma by degrading p16. Cancer Sci. 2020;111(7):2635\u201346.","journal-title":"Cancer Sci"},{"issue":"11","key":"395_CR17","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.7150\/ijbs.72397","volume":"18","author":"X Zhu","year":"2022","unstructured":"Zhu X, et al. DNMT3B-mediated FAM111B methylation promotes papillary thyroid tumor glycolysis, growth and metastasis. Int J Biol Sci. 2022;18(11):4372\u201387.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"395_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12032-024-02554-8","volume":"42","author":"J Yin","year":"2024","unstructured":"Yin J, et al. PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B. Med Oncol. 2024;42(1):6.","journal-title":"Med Oncol"},{"issue":"1","key":"395_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/tox.23965","volume":"39","author":"Y Yang","year":"2024","unstructured":"Yang Y, et al. Family with sequence similarity 111 member B contributes to tumor growth and metastasis by mediating cell proliferation, invasion, and EMT via transforming acidic coiled-coil protein 3\/PI3K\/AKT signaling pathway in hepatocellular carcinoma. Environ Toxicol. 2024;39(1):409\u201320.","journal-title":"Environ Toxicol"},{"issue":"12","key":"395_CR20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1177\/15353702231160326","volume":"248","author":"W Wang","year":"2023","unstructured":"Wang W, et al. Silencing of FAM111B inhibits tumor growth and promotes apoptosis by decreasing AKT activity in ovarian cancer. Exp Biol Med (Maywood). 2023;248(12):1043\u201355.","journal-title":"Exp Biol Med (Maywood)"},{"key":"395_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"395_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13578-020-00416-0","volume":"10","author":"F Xu","year":"2020","unstructured":"Xu F, et al. Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2020;10(1):54.","journal-title":"Cell Biosci"},{"issue":"10","key":"395_CR23","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a003236","volume":"2","author":"EY Lee","year":"2010","unstructured":"Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010;2(10): a003236.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"395_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74\u201388.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"395_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2014.11.008","volume":"27","author":"S Schwartz","year":"2015","unstructured":"Schwartz S, et al. Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta. Cancer Cell. 2015;27(1):109\u201322.","journal-title":"Cancer Cell"},{"issue":"9","key":"395_CR26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2443","volume":"8","author":"LM Amzel","year":"2008","unstructured":"Amzel LM, et al. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer. 2008;8(9):665\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"395_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","volume":"20","author":"B Bilanges","year":"2019","unstructured":"Bilanges B, Posor Y, Vanhaesebroeck B. PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol. 2019;20(9):515\u201334.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"395_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, et al. The PI3K pathway in human disease. Cell. 2017;170(4):605\u201335.","journal-title":"Cell"},{"issue":"20","key":"395_CR29","doi-asserted-by":"publisher","first-page":"14278","DOI":"10.1021\/acs.jmedchem.3c01319","volume":"26","author":"M K\u00fcc\u00fckdisli","year":"2023","unstructured":"K\u00fcc\u00fckdisli M, et al. Structural basis for highly selective class II alpha phosphoinositide-3-kinase inhibition. J Med Chem. 2023;26(20):14278\u2013302.","journal-title":"J Med Chem."},{"issue":"8","key":"395_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"395_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7\u201324.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"395_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41573-022-00582-5","volume":"22","author":"JE Burke","year":"2023","unstructured":"Burke JE, Triscott J, et al. Beyond PI3Ks: targeting phosphoinositide kinases in disease. Nat Rev Drug Discov. 2023;22(5):357\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"395_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.semcancer.2019.04.001","volume":"59","author":"Q Yang","year":"2019","unstructured":"Yang Q, Jiang W, Hou P. Emerging role of PI3K\/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112\u201324.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"395_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12079-022-00702-1","volume":"17","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, et al. Targeting PI3K\/Akt signaling in prostate cancer therapy. J Cell Commun Signal. 2023;17(3):423\u201343.","journal-title":"J Cell Commun Signal"},{"key":"395_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/978-3-030-32656-2_14","volume":"1210","author":"Y Yan","year":"2019","unstructured":"Yan Y, Huang H. Interplay Among PI3K\/AKT, PTEN\/FOXO and AR Signaling in Prostate Cancer. Adv Exp Med Biol. 2019;1210:319\u201331.","journal-title":"Adv Exp Med Biol"},{"key":"395_CR36","doi-asserted-by":"publisher","first-page":"106553","DOI":"10.1016\/j.phrs.2022.106553","volume":"187","author":"MDA Paskeh","year":"2023","unstructured":"Paskeh MDA, et al. Biological impact and therapeutic perspective of targeting PI3K\/Akt signaling in hepatocellular carcinoma: promises and challenges. Pharmacol Res. 2023;187:106553.","journal-title":"Pharmacol Res"},{"issue":"7","key":"395_CR37","first-page":"4426","volume":"14","author":"Z Wu","year":"2022","unstructured":"Wu Z, et al. The role of PI3K\/AKT signaling pathway in gallbladder carcinoma. Am J Transl Res. 2022;14(7):4426\u201342.","journal-title":"Am J Transl Res"},{"issue":"13","key":"395_CR38","doi-asserted-by":"publisher","first-page":"108196","DOI":"10.1016\/j.celrep.2020.108196","volume":"32","author":"S Xie","year":"2020","unstructured":"Xie S, et al. Divergent roles of PI3K isoforms in PTEN-deficient glioblastomas. Cell Rep. 2020;32(13):108196.","journal-title":"Cell Rep"},{"issue":"5","key":"395_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273\u201391.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"395_CR40","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/neuonc\/noac064","volume":"24","author":"E Mohamed","year":"2022","unstructured":"Mohamed E, et al. PI3K\/AKT\/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro Oncol. 2022;24(9):1471\u201381.","journal-title":"Neuro Oncol"},{"issue":"10","key":"395_CR41","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1200\/JCO.2005.03.089","volume":"23","author":"F Lefranc","year":"2005","unstructured":"Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005;23(10):2411\u201322.","journal-title":"J Clin Oncol"}],"container-title":["Chinese Neurosurgical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41016-025-00395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41016-025-00395-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41016-025-00395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:03:50Z","timestamp":1747631030000},"score":1,"resource":{"primary":{"URL":"https:\/\/cnjournal.biomedcentral.com\/articles\/10.1186\/s41016-025-00395-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1186\/s41016-025-00395-6","relation":{},"ISSN":["2057-4967"],"issn-type":[{"value":"2057-4967","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were approved by the Ethics Committee of the Hangzhou First People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest. All authors\u2019 financial relationships are completely independent, and they have no affiliation with any other individuals or organizations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}